Amylin Pharmaceuticals Inc. and partner Takeda Pharmaceutical Co. Ltd. have discontinued development of combination obesity candidate pramlintide/metreleptin after what they described as a "commercial reassessment" of a revised development plan and the "evolving dynamics" of obesity therapeutics.